Detection and therapy of neuroblastoma minimal residual disease using [(64/67)Cu]Cu-SARTATE in a preclinical model of hepatic metastases

BACKGROUND: A major challenge to the long-term success of neuroblastoma therapy is widespread metastases that survive initial therapy as minimal residual disease (MRD). The SSTR2 receptor is expressed by most neuroblastoma tumors making it an attractive target for molecularly targeted radionuclide t...

Descripción completa

Detalles Bibliográficos
Autores principales: Dearling, Jason L. J., van Dam, Ellen M., Harris, Matthew J., Packard, Alan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907331/
https://www.ncbi.nlm.nih.gov/pubmed/33630166
http://dx.doi.org/10.1186/s13550-021-00763-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907331/
https://www.ncbi.nlm.nih.gov/pubmed/33630166
http://dx.doi.org/10.1186/s13550-021-00763-0

Ejemplares similares